ESPR common stock will cease trading on Nasdaq; holders should expect to receive $3.16 per share in cash plus one CVR per share. The CVRs are non-transferable and contingent on achieving sales milestones for NEXLETOL/NEXLIZET (2027) and ENBUMYST (through 2030). Monitor future announcements regarding milestone achievement for potential CVR value realization.
Drugs in focus
ESPR drug pipeline →NEXLIZET
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized (since February 2020)
- Next catalyst
- None dated
What to watchESPR common stock has been acquired by ARCHIMED at $3.16/share with the deal closing July 13, 2026. Holders received one non-transferable Contingent Value Right (CVR) per share, entitling them to potential milestone payments tied to NEXLETOL/NEXLIZET U.S. net sales (starting 2027) and ENBUMYST (through 2030). There is no further tradeable equity vehicle, the stock will be delisted.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Esperion Therapeutics completed its acquisition by ArchiMed (via Essence Parent Inc.) on July 13, 2026, for $3.16 per share in cash plus one contingent value right (CVR) per share, representing up to $100M in aggregate milestone payments. The merger triggers delisting from Nasdaq, a change of control, replacement of the board, and termination of the prior credit agreement with new debt financing from BioPharma Credit.
Key Financial Metrics
Key Facts
- Merger completed on July 13, 2026; each share converted into $3.16 cash plus one CVR
- Total cash consideration approximately $1.1 billion, funded by equity and debt from BioPharma Credit
- CVRs entitle holders to up to $100M aggregate contingent payments tied to U.S. net sales milestones for NEXLETOL/NEXLIZET (bempedoic acid) and ENBUMYST (bumetanide)
- Common stock to be delisted from Nasdaq; Form 15 to be filed to suspend SEC reporting obligations
- All prior directors resigned; Justin Bateman and Ankit Pareek appointed as new directors
- Prior credit agreement with GLAS USA LLC terminated and repaid in full
- New loan agreement entered with BioPharma Credit PLC and affiliates
Financial Impact
Cash consideration of approximately $1.1 billion plus CVRs with up to $100M in aggregate milestone payments
Risk Factors
- CVR milestones may not be achieved, resulting in no additional payments
- No further liquidity for common stock after delisting
- CVRs are non-transferable and cannot be traded
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-082926 |
| Document: tm2620034d3_ex3-2.htm | 0001104659-26-082926 |
| Document: tm2620034d3_8k.htm | 0001104659-26-082926 |
| Document: tm2620034d3_ex4-1.htm | 0001104659-26-082926 |
| Document: tm2620034d3_ex3-1.htm | 0001104659-26-082926 |
| Document: 0001104659-26-082926-index-headers.html | 0001104659-26-082926 |
| Document: 0001104659-26-082926-index.html | 0001104659-26-082926 |
| Document: 0001104659-26-082926.txt | 0001104659-26-082926 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Viewing Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers